Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.

@article{Deedwania2005EfficacySA,
  title={Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.},
  author={Prakash C. Deedwania and Thomas D. Giles and Michael I Klibaner and Jalal K. Ghali and Johan Herlitz and P. D. Hildebrandt and John K. Kjekshus and Jindrich Spinar and Jir{\'i} V{\'i}tovec and Hilary S. Stanbrook and John Wikstrand},
  journal={American heart journal},
  year={2005},
  volume={149 1},
  pages={159-67}
}
BACKGROUND The objective of the current study was to examine the efficacy and tolerability of the beta-blocker metoprolol succinate controlled release/extended release (CR/XL) in patients with diabetes in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). METHODS The Cox proportional hazards model was used to calculate hazard ratios (HR) for convenience expressed as relative risks (risk reduction = 1-HR), and 95% confidence intervals (CI). RESULTS The… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Regardless of diabetic status , a highly significant reduction in hospitalizations for heart failure was observed with metoprolol CR / XL therapy , which was very well tolerated also by patients with diabetes .
Efficacy , safety and tolerability of metoprolol CR / XL in patients with diabetes and chronic heart failure : experiences from MERIT - HF .
Efficacy , safety and tolerability of metoprolol CR / XL in patients with diabetes and chronic heart failure : experiences from MERIT - HF .
Patients with heart failure and diabetes have a much higher risk of hospitalization than patients without diabetes .
Metoprolol CR / XL was well tolerated and reduced the risk of hospitalization for heart failure by 37% in the diabetic group ( 95% CI 53% to 15% ) , and by 35% in the non - diabetic group ( 95% CI 48% to 19% ) .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Metoprolol CR / XL was well tolerated and reduced the risk of hospitalization for heart failure by 37% in the diabetic group ( 95% CI 53% to 15% ) , and by 35% in the non - diabetic group ( 95% CI 48% to 19% ) .
Regardless of diabetic status , a highly significant reduction in hospitalizations for heart failure was observed with metoprolol CR / XL therapy , which was very well tolerated also by patients with diabetes .
Patients with heart failure and diabetes have a much higher risk of hospitalization than patients without diabetes .
The objective of the current study was to examine the efficacy and tolerability of the beta - blocker metoprolol succinate controlled release / extended release ( CR / XL ) in patients with diabetes in the Metoprolol CR / XL Randomized Intervention Trial in Chronic Heart Failure ( MERIT - HF ) .
The objective of the current study was to examine the efficacy and tolerability of the beta - blocker metoprolol succinate controlled release / extended release ( CR / XL ) in patients with diabetes in the Metoprolol CR / XL Randomized Intervention Trial in Chronic Heart Failure ( MERIT - HF ) .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Metoprolol CR / XL was well tolerated and reduced the risk of hospitalization for heart failure by 37% in the diabetic group ( 95% CI 53% to 15% ) , and by 35% in the non - diabetic group ( 95% CI 48% to 19% ) .
Metoprolol CR / XL was well tolerated and reduced the risk of hospitalization for heart failure by 37% in the diabetic group ( 95% CI 53% to 15% ) , and by 35% in the non - diabetic group ( 95% CI 48% to 19% ) .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Efficacy , safety and tolerability of metoprolol CR / XL in patients with diabetes and chronic heart failure : experiences from MERIT - HF .
Patients with heart failure and diabetes have a much higher risk of hospitalization than patients without diabetes .
Patients with heart failure and diabetes have a much higher risk of hospitalization than patients without diabetes .
The objective of the current study was to examine the efficacy and tolerability of the beta - blocker metoprolol succinate controlled release / extended release ( CR / XL ) in patients with diabetes in the Metoprolol CR / XL Randomized Intervention Trial in Chronic Heart Failure ( MERIT - HF ) .
Regardless of diabetic status , a highly significant reduction in hospitalizations for heart failure was observed with metoprolol CR / XL therapy , which was very well tolerated also by patients with diabetes .
Regardless of diabetic status , a highly significant reduction in hospitalizations for heart failure was observed with metoprolol CR / XL therapy , which was very well tolerated also by patients with diabetes .
The objective of the current study was to examine the efficacy and tolerability of the beta - blocker metoprolol succinate controlled release / extended release ( CR / XL ) in patients with diabetes in the Metoprolol CR / XL Randomized Intervention Trial in Chronic Heart Failure ( MERIT - HF ) .
Efficacy , safety and tolerability of metoprolol CR / XL in patients with diabetes and chronic heart failure : experiences from MERIT - HF .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II ( CIBIS II ) , MERIT - HF , and the Carvedilol Prospective Randomized Cumulative Survival Study ( COPERNICUS ) showed similar survival benefits in patients with diabetes ( 25% ; 95% CI 40% to 4% ) and without diabetes ( 36% ; 95% CI 44% to 27% ) ; test of diabetes by treatment interaction was non - significant .
The objective of the current study was to examine the efficacy and tolerability of the beta - blocker metoprolol succinate controlled release / extended release ( CR / XL ) in patients with diabetes in the Metoprolol CR / XL Randomized Intervention Trial in Chronic Heart Failure ( MERIT - HF ) .
All Topics